Antibody–drug conjugates come of age in oncology
Charles Dumontet(Centre de Recherche en Cancérologie de Lyon), Alain Beck(Centro de Investigacion Principe Felipe), Janice M. Reichert(Framingham State University), John M. Lambert(University of Illinois Urbana-Champaign), Peter D. Senter(Seagen (United States))
Cited by 772
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Antibody-Drug Conjugates in Cancer Therapy
|Annual Review of Medicine|2012|763